Methylation test to predict melanoma recurrence after surgery

Who could benefit from this research

What this research studies

This project aims to validate a methylation-based test that analyzes tumor samples to forecast recurrence risk in people with stage II melanoma who have had tumor removal. It focuses on translating a complex genomic assay into a clinically useful tool that can guide adjuvant treatment decisions. The study builds on prior findings that specific DNA methylation patterns relate to outcomes, and it seeks robust, clinically valid results using the EPIC 900K beadchip platform.

Why it matters

Where this research is happening

• New York University School of Medicine
  New York, United States Active

Researchers

• Principal investigator: Polsky, David — New York University School of Medicine
• Study coordinator: Polsky, David

Related research

Other NIH-funded projects on the same topics.

• AI to predict melanoma coming back using tumor images, gene data, and pathology

  This project is building an AI tool that uses detailed tumor pictures, gene activity, and pathology reports to help doctors predict whether early-stage (stage I or II) melanoma might return.

  NIH research University of Chicago · Chicago, United States · NIH-11457144

• Dormant melanoma cells and aging: how the tissue environment shapes recurrence

  This NIH grant studies how aging tissue environments influence melanoma dormancy and late recurrences, with a focus on how aged lung fibroblasts and Wnt signaling affect cancer cell reawakening.

  NIH research Johns Hopkins University · Baltimore, United States · NIH-11370310

• A new test to predict melanoma recurrence using DNA analysis

  This study is looking to create a new test that checks DNA markers in patients with stage II melanoma to better predict if their cancer might come back, helping doctors decide who might need extra treatment and who can avoid unnecessary ones.

  NIH research New York University School of Medicine · New York, United States · NIH-11039026

• Using advanced AI to predict melanoma recurrence by analyzing imaging and genetic data.

  This study is looking to help people with early-stage melanoma by using advanced imaging and genetic information to better predict if their cancer might come back, so they can receive more personalized care and monitoring based on their specific risk.

  NIH research Massachusetts General Hospital · Boston, United States · NIH-11032046

• Keloid recurrence study using multi-omics in diverse patients

  A research effort will look at why keloids come back after surgery, especially in African American patients, using comprehensive molecular data from patient samples.

  NIH research Henry Ford Health + Michigan State University Health Sciences · East Lansing, United States · NIH-11641647

• Combined Imaging and RNA Markers to Predict Head and Neck Cancer Recurrence

  A research project aims to use imaging and RNA data to better predict if head and neck cancer will come back, helping doctors tailor treatments for patients.

  NIH research Washington University · Saint Louis, United States · NIH-11607780

About this research

1. This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
2. Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
3. For full project details, budget, and progress reports, visit the official NIH RePORTER page.